Compare · ABT vs CORT
ABT vs CORT
Side-by-side comparison of Abbott Laboratories (ABT) and Corcept Therapeutics Incorporated (CORT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and CORT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $182.59B, about 14.8x CORT ($12.32B).
- Over the past year, ABT is down 20.0% and CORT is up 62.2% - CORT leads by 82.2 points.
- CORT has been more active in the news (15 items in the past 4 weeks vs 10 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 17 for CORT).
- Company
- Abbott Laboratories
- Corcept Therapeutics Incorporated
- Price
- $105.62+0.04%
- $116.29+1.95%
- Market cap
- $182.59B
- $12.32B
- 1M return
- -2.82%
- +1.76%
- 1Y return
- -19.99%
- +62.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 10
- 15
- Recent ratings
- 25
- 17
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Latest ABT
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
Latest CORT
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Chief Development Officer Guyer William was granted 328 shares, increasing direct ownership by 8% to 4,313 units (SEC Form 4)
- Officer Maduck Sean covered exercise/tax liability with 117 shares, exercised 25,000 shares at a strike of $8.27, sold $2,860,737 worth of shares (25,000 units at $114.43) as part of a pre-agreed trading plan and was granted 300 shares, increasing direct ownership by 2% to 9,938 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mokari Atabak covered exercise/tax liability with 102 shares and was granted 276 shares, increasing direct ownership by 1% to 16,304 units (SEC Form 4) (withholding obligation)
- Chief Business Officer Robb Gary Charles was granted 328 shares and covered exercise/tax liability with 91 shares, increasing direct ownership by 2% to 13,663 units (SEC Form 4) to satisfy withholding obligation
- President, Oncology Vieira Roberto Wandenkolk was granted 276 shares, covered exercise/tax liability with 102 shares, exercised 58,333 shares at a strike of $21.63 and sold $6,460,766 worth of shares (58,333 units at $110.76) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 4,242 units (SEC Form 4) to cover withholding tax
- Officer Lyon Joseph Douglas was granted 260 shares and covered exercise/tax liability with 72 shares, increasing direct ownership by 3% to 5,683 units (SEC Form 4) to cover taxes
- New insider Vieira Roberto Wandenkolk claimed ownership of 4,068 shares (SEC Form 3)
- Director Park Kimberly exercised 30,000 shares at a strike of $13.49, covered exercise/tax liability with 3,315 shares and sold $3,270,169 worth of shares (26,685 units at $122.55) (SEC Form 4)
- Officer Maduck Sean exercised 30,955 shares at a strike of $11.35 and sold $3,887,320 worth of shares (30,955 units at $125.58) as part of a pre-agreed trading plan (SEC Form 4)